Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
600196
Rang in aandelen
#2197
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical... Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Aandeelprijs
$3.40
Marktkapitalisatie
$9.07B
Verandering (1 dag)
-1.61%
Verandering (1 jaar)
-16.08%
Land
CN
Handel Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Categorie
Healthcare
Winst voor Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Shanghai Fosun Pharmaceutical (Group) Co., Ltd. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Shanghai Fosun Pharmaceutical (Group) Co., Ltd. van 2001 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $730.66M | 27.92% |
| 2024 | $571.20M | 23.86% |
| 2023 | $461.19M | -30.46% |
| 2022 | $663.16M | -30.25% |
| 2021 | $950.72M | 32.77% |
| 2020 | $716.07M | 10.17% |
| 2019 | $649.94M | 24.89% |
| 2018 | $520.40M | -16.64% |
| 2017 | $624.28M | 21.36% |
| 2016 | $514.42M | -0.93% |
| 2015 | $519.24M | 18.33% |
| 2014 | $438.82M | 15.05% |
| 2013 | $381.42M | 12.03% |
| 2012 | $340.46M | 24.30% |
| 2011 | $273.89M | 50.41% |
| 2010 | $182.10M | -61.92% |
| 2009 | $478.18M | 290.45% |
| 2008 | $122.47M | 18.23% |
| 2007 | $103.59M | 135.84% |
| 2006 | $43.92M | 31.65% |
| 2005 | $33.36M | 92.26% |
| 2004 | $17.35M | -58.15% |
| 2003 | $41.46M | 96.02% |
| 2002 | $21.15M | 8.96% |
| 2001 | $19.41M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
